Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.13 (
protein kinase C
)
49,245
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have reviewed the literature, which supports an important role for dopamine withdrawal in the regulation of
PRL
secretion. Concentrations of dopamine in the hypophyseal portal circulation are sufficient to occupy the majority of dopamine receptors (1) and tonically suppress
PRL
secretion (20-26). Brief escapes from dopaminergic regulation associated with the secretion of
PRL
have been observed (37-41). Therefore, dopamine regulates secretion of
PRL
both by occupancy of, as well as dissociation from, specific D2 dopamine receptors. The rapid off rate from its receptor (2) is consistent with signals transmitted through brief decreases in dopamine concentration. The removal of dopamine for 10 min results in increases in intracellular cAMP and presumably activation of protein kinase A (39, 138) as well as activation of phospholipase C (137, 138) and
protein kinase C
(136). The removal of dopamine results directly in the release of
PRL
(37-41). Furthermore, the brief removal of dopamine results in the long-term potentiation of the
PRL
-releasing action of TRH (38-40). The potentiating action of dopamine withdrawal appears to be mediated by the activation of protein kinase A since pretreatment with VIP, a hormone that signals via protein kinase A, also potentiates the action of TRH (39). TRH stimulates
PRL
release via Ca2+/
protein kinase C
(177-184). The potentiating action of dopamine removal is selective for the Ca2+/
protein kinase C
pathway since dopamine removal does not potentiate the
PRL
-secreting action of VIP (38, 87, 92). The action of TRH is potentiated up to 30 min after the return of dopamine and the suppression of
PRL
to basal levels (38). In Fig. 10, dopamine dissociation from its receptor or VIP association to its receptor are shown separated by a broken line to indicate that by the time the potentiation of the action of TRH is tested, either dopamine is again occupying its receptor or VIP is no longer present. Therefore, the effect of protein kinase A activation is remembered by the lactotroph. We hypothesize that the responsiveness of the cell to TRH is potentiated by the phosphorylation of proteins by protein kinase A. Two potential substrates for protein kinase A are voltage-dependent Ca2+ channels and protein phosphatase inhibitors that would prolong the action of
protein kinase C
. When TRH occupies its receptor, intracellular Ca2+ levels are increased first from intracellular stores and subsequently by extracellular Ca2+ influx (187-189). Intracellular Ca2+ is mobilized by increased levels of IP3(128). Extracellular Ca2+ enters the lactotroph via voltage-dependent Ca2+ channels (189, 190).(ABSTRACT TRUNCATED AT 400 WORDS)
...
PMID:Dissociation of dopamine from its receptor as a signal in the pleiotropic hypothalamic regulation of prolactin secretion. 161 63
TRH regulates
PRL
secretion and synthesis in GH4C1 rat pituitary cells. TRH responses are associated with activation of
protein kinase C
(
PKC
) isozymes and elevation of cytosolic calcium. To determine which
PKC
isozymes are involved in TRH-directed responses, we evaluated the effect of TRH on GH cell alpha-, beta-, delta-, and epsilon-
PKC
isozymes. Immunoblot analysis demonstrated that TRH caused rapid redistribution of all isozymes to a Triton X-100-insoluble (i.e. cytoskeletal) fraction. Corollary immunocytofluorescence studies demonstrated that redistributed PKCs accumulate in cell peripheries. Exocytosis involves reorganization of the cytoskeleton, therefore, each of the GH cell PKCs is appropriately located to phosphorylate proteins important for cytoskeleton organization. To determine the relative contributions of calcium and
PKC
signal transduction pathways in mediating TRH responses, the effects of potassium depolarization (which increases cytosolic calcium) and phorbol dibutyrate (which activates all
PKC
isozymes without increasing calcium) were compared. The data indicate that TRH-mediated reorganization of vinculin proceeds via a calcium-mediated pathway, whereas fragmentation of actin filaments proceeds via a
PKC
-dependent pathway. Selective down-modulation of epsilon-
PKC
with prolonged TRH-treatment was used to demonstrate that epsilon-
PKC
is not necessary for certain TRH-stimulated biological responses.
...
PMID:Hormone- and phorbol ester-activated protein kinase C isozymes mediate a reorganization of the actin cytoskeleton associated with prolactin secretion in GH4C1 cells. 173 65
Mediation by Ca2+ of TRH action on the
PRL
promoter was investigated by both additivity and pharmacological studies and by techniques that probe more gene-proximal events. TRH required the presence of Ca2+ in the medium for stimulation of transient expression in GH3 cells of a
PRL
-chloramphenicol acetyltransferase (PRL-CAT) construct containing proximal
PRL
promoter sequences [(-187)
PRL
-CAT]. Chronic 12-O-tetradecanoyl phorbol-13-acetate down-regulation of cellular
protein kinase C
did not block induction of expression of (-187)
PRL
-CAT by either Ca2+ or TRH. In studies with Ca2+ blockers, the Ca2+ flux inhibitors cobalt ion and nimodipine blocked induction of (-187)
PRL
-CAT expression by either Ca2+ or TRH. On the other hand, the Ca2+ immobilizers 1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyltetraester and 8-(N,N-diethylamino)octyl 3,4,5-trimethoxybenzoate blocked induction of expression of this construct by Ca2+ but not by TRH, suggesting that TRH regulation of the
PRL
promoter may be dependent on Ca2+ fluxes but insensitive to Ca2+ immobilization. We have shown previously that the
PRL
promoter pit-1 binding site 1P is a TRH response element. In the present studies, Ca2+ regulation studies with 5'-deletion mutants of (-204)
PRL
-CAT showed that (-75)
PRL
-CAT, containing the single pit-1 binding site 1P, also contains a Ca2+ response element. The observation that two copies of a site 1P oligomer transferred a Ca2+ response to either of the two minimal constructs (-39)
PRL
-CAT or (-39)mouse metallothionein-CAT showed that site 1P is an independent Ca2+ response element. Analysis of site 1P mutants yielded a strong correlation between the ability to bind pit-1 and to transfer a Ca2+ response. In addition, coexpression of a mutant pit-1 possessing reduced trans-activational activity strongly inhibited TRH regulation of (-187)
PRL
-CAT and partially blocked Ca2+ regulation of this construct. We conclude that Ca2+ mediates TRH action on the
PRL
promoter, and that pit-1 represents a gene-proximal mediator in this signalling pathway.
...
PMID:Mediation by calcium of thyrotropin--releasing hormone action on the prolactin promoter via transcription factor pit-1. 177 32
Estrogens have been known to induce
PRL
cell hyperplasia in the anterior pituitary of some species for many decades. Recent studies have shown variable susceptibility to estrogen-induced hyperplasia in different strains of rats. The distinction between hyperplastic pituitaries and adenomas is usually not made by most investigators in this field, although true neoplasms can usually be propagated by serial transplantation. The growth of transplantable tumors is usually inhibited by estrogen in vivo. Estrogens have a biphasic effect on pituitary cell proliferation in vitro with higher concentrations of estradiol inhibit cell growth, and lower concentrations stimulating
PRL
secretion. Estrogens can regulate
PRL
gene methylation in vivo thus affecting
PRL
mRNA expression. Recent studies have suggested that estrogen regulates signal transduction by stimulating
protein kinase C
. Estrogens also regulate specific proto-oncogenes such as c-myc and c-fos. These observations may help to explain some of the regulatory effects of estrogens on cell proliferation and tumor development.
...
PMID:Effects of estrogens on pituitary cell and pituitary tumor growth. 192 54
A somatomammotropic cell line (P0) derived from adult rat pituitaries has been maintained in culture for 2 yr. Secretion of GH and
PRL
by this cell line has been studied in response to hypophysiotropic peptides known to affect the release of both hormones as well as agents that affect second messenger systems in an attempt to characterize the stimulus-secretion mechanisms used by these cells. GH and
PRL
release during short term (4 h) incubations of P0 cells and primary cultures of dispersed rat pituitary cells was initially measured in response to GRF, TRH, vasoactive intestinal peptide (VIP), and SRIF. In P0 cells, the minimal effective dose of each of the hypophysiotropic peptides was comparable with respect to GH and
PRL
secretion. The effects of TRH and VIP were similar to those in freshly dispersed cells with respect to
PRL
release, whereas those of GRF and SRIF were less potent with respect to GH release. The stimulation of GH and
PRL
release in P0 cells by adenylate cyclase-related agents ((Bu)2 cAMP and forskolin) was comparable to that for GH secretion in mature somatotrophs but much greater than that of
PRL
release in mature lactotrophs. Stimulation of GH and
PRL
release in P0 cells by
protein kinase C
-related agents (diacylglycerol and phorbol ester) was also similar to that observed for GH release from mature pituitary cells, whereas minimal or undetectable effects were observed on
PRL
release from mature cells. The results indicate that the P0 somatomammotropic cell line possesses receptors, second messenger systems, and secretory characteristics of both somatotrophs and lactotrophs, although where differences exist, there is more resemblance to somatotrophs. They also demonstrate that the responses to each of the agents studied are bihormonal and appear to be regulated by a common mechanism.
...
PMID:Growth hormone and prolactin secretion in cultured somatomammotroph cells. 197 45
Stimulation of cultured hypothalamic slices with
PRL
causes a rapid translocation of a Ca2+/phospholipid dependent protein kinase from the cytosol to the membrane fraction. The translocation of
PKC
from the cytosol to the membrane occurred at physiological concentrations of
PRL
with a maximal response occurring at 10(-10) M. At concentrations above this, there was less
PKC
activity translocated from the cytosol to the membrane. When injected into the medial preoptic area of the hypothalamus,
PRL
resulted in a similar translocation of
PKC
activity. These data clearly indicate that
PRL
can activate
PKC
in the rat hypothalamus, and suggest that
PKC
may be one of the transmembrane signaling mechanisms involved in the regulation of brain function by prolactin.
...
PMID:Prolactin stimulation of protein kinase C activity in the rat hypothalamus. 202 80
We have reported previously that anterior pituitary cells released interleukin-6 (IL-6) and that this release was stimulated by lipopolysaccharide (LPS), phorbol myristate acetate (PMA), or agents that increased intracellular cAMP concentrations. We now report that IL-1 stimulates IL-6 release from anterior pituitary cells in vitro. IL-1 alpha and IL-1 beta (0.04-25 ng/ml) significantly increased IL-6 release 3- to 4-fold in a concentration-related manner during 6-h incubations; however, there was no change in extracellular or intracellular cAMP concentrations. IL-1 alpha and IL-1 beta (10 ng/ml), vasoactive intestinal peptide (VIP, 500 nM), prostaglandin E2 (PGE2, 1 microM), and LPS (1 ng/ml) stimulated IL-6 release to a similar degree. In the presence of VIP and PGE2, IL-1 alpha and IL-1 beta increased IL-6 release without any apparent further change in extracellular or intracellular cAMP. Conversely, LPS did not increase cAMP concentrations, and IL-1 did not significantly increase IL-6 release in the presence of LPS. The preexposure of anterior pituitary cells to 1 microM PMA caused the apparent down-regulation of
protein kinase C
activity because 100 nM PMA was no longer effective to stimulate IL-6 release; however, the ability of IL-1 alpha, IL-1 beta, PGE2, or LPS to stimulate IL-6 release was not altered. In addition, IL-1 alpha and IL-1 beta stimulated IL-6 release in the presence of maximally stimulative concentrations of PMA. The synthetic glucocorticoid dexamethasone (10 nM) significantly inhibited IL-6 release induced by IL-1 alpha, IL-1 beta, or LPS. The separation of anterior pituitary cells on unit gravity BSA gradients generated fractions of IL-6-producing cells that were inducible by LPS and IL-1 beta and separate from the
PRL
-, ACTH-, GH-, or LH-producing cell fractions. These data suggest that IL-1 stimulates IL-6 release from a subpopulation of anterior pituitary cells via a glucocorticoid-sensitive and non-cAMP-mediated pathway that is different from those pathways used by VIP, PGE2, and PMA.
...
PMID:Interleukin-1 stimulates interleukin-6 release from rat anterior pituitary cells in vitro. 203 55
In order to study the mechanism of GH secretion from somatotroph adenoma cells, we have compared the effect of 12-O-tetradecanoyl phorbol-13-acetate (TPA) with that of growth hormone releasing factor (GRF) on GH secretion from human somatotroph adenoma cells cultured in monolayer. Pituitary adenoma cells were obtained from 13 patients with acromegaly undergoing surgery. On the 7th day of culture, the cells were exposed for 2 h to secretagogues. All 13 adenoma cell cultures (100%) responded to TPA (1.6-16.0 nmol/l) with a two- to six-fold increase in GH release (240 +/- 37% increase of control: mean +/- SE). The response was detectable within 10 min, and was maximal at 2 h. Phospholipase C (7.7 mmol/l) also stimulated a two- to ten-fold increase in GH release in all four adenomas examined (100%). GH release was stimulated by GRF (2.0 nmol/l) in eight out of 12 adenoma cells (67%), but the magnitude of the responses to GRF (60 +/- 18% increase of control: mean +/- SE) were much smaller than that of TPA. Five out of 13 adenomas secreted detectable amount of
PRL
into the medium and these five adenomas (100%) responded to TPA (16.0 nmol/l) with a two- to six-fold increase. These observations indicate that the activation of
protein kinase C
is the consistent stimulator in GH and
PRL
secretion in human somatotroph adenoma cells. However, it is not determined whether the
protein kinase C
is involved in the in-vivo production of GH in patients with acromegaly.
...
PMID:Phorbol ester, not growth hormone releasing factor, consistently stimulates growth hormone release from somatotroph adenomas in culture. 206 Jan 47
TRH and phorbol dibutyrate (PDBu) stimulate
PRL
secretion and synthesis from GH4C1 rat pituitary cells through activation of
protein kinase C
(
PKC
). TRH responses are mediated by increases in cellular levels of two
PKC
activators, Ca2+ and diacylglycerol (DAG), whereas PDBu acts as a DAG analog. We conducted experiments to compare the effects of Ca2+ and PDBu/DAG on alpha-
PKC
redistribution and to determine to what components of the particulate fraction activated alpha-
PKC
associates. Subcellular fractionation experiments demonstrated that TRH and PDBu both caused chelator-stable association of alpha-
PKC
with the particulate fraction. In contrast, Ca2+-mediated association with the particulate fraction was not chelator stable. Immunocytofluorescence experiments also demonstrated that TRH, PDBu, and increased cytosolic Ca2+ (due to ionomycin or K+ depolarization) caused redistribution. The effect of TRH was rapid and transient, similar to TRH stimulation of phospholipase C. The translocated alpha-
PKC
in the particulate fraction from TRH- or PDBu-treated cultures was not solubilized with Triton X-100. In comparable studies using an immunofluorescence assay, alpha-
PKC
immunofluorescence remained in detergent-insoluble preparations from TRH- and PDBu-stimulated, but not resting cells. The association of activated alpha-
PKC
with chelator- and detergent-insoluble material suggested that activated alpha-
PKC
may be associated with membrane and cytoskeletal components.
...
PMID:Activation of alpha-protein kinase C leads to association with detergent-insoluble components of GH4C1 cells. 210 89
Calcitonin is present in both the hypothalamus and pituitary of the rat, and normal rat anterior pituitary cells express calcitonin receptors. Calcitonin has been reported to inhibit or to stimulate
PRL
release from rat anterior pituitary cells. We have investigated the effects of salmon calcitonin on basal and stimulated
PRL
release from rat anterior pituitary cells and have studied the effects of this peptide on the intracellular biochemical pathways involved in
PRL
release. Salmon calcitonin had no significant effect on basal
PRL
release, but inhibited (P less than 0.01) TRH-stimulated
PRL
release without affecting
PRL
release promoted by angiotensin II, neurotensin, phorbol myristate acetate (a
protein kinase C
activator), or maitotoxin (a calcium channel activator). Salmon calcitonin had no effect on the increase in
PRL
release and intracellular cAMP concentration after exposure of pituitary cells to vasoactive intestinal peptide or forskolin. Salmon calcitonin significantly decreased (P less than 0.01) the TRH-stimulated rise in inositol phosphates without affecting the angiotensin II-stimulated increase in inositol phosphates. Similarly, salmon calcitonin decreased the TRH-stimulated increase in cytosolic calcium and arachidonate liberation by pituitary cells. We conclude that salmon calcitonin selectively decreases TRH-stimulated
PRL
release by a mechanism that involves a decrease in inositol phosphate production, as well as a subsequent reduction in cytosolic calcium levels and in arachidonate liberation.
...
PMID:Calcitonin decreases thyrotropin-releasing hormone-stimulated prolactin release through a mechanism that involves inhibition of inositol phosphate production. 216 10
1
2
3
4
5
6
Next >>